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he percutaneous treatment of mitral regurgitation (MR) is now a cl
reality, with multiple innovative devices in proof of concept and feas
trials and one device well into a pivotal study. More than 350 percut
itral valve repair procedures have been performed with at least 6 different d
n the past 3 years. Whereas progress has been rapid and early clinical effic
een demonstrated in transcatheter aortic valve therapy, the demonstratio
linical benefit has been somewhat more elusive in percutaneous mitral 
herapy. This development scenario is the opposite of what was widely antic
 years ago, as preclinical proof of concept studies were completed and the
ew world of clinical transcatheter valve therapy was about to commence. It s
hat that the larger clinical unmet need and greater safety margins for transc
itral valve therapy would drive the clinical adoption of this technology much
han aortic interventions. However, a number of issues have proven problema
he road to clinical reality, including the inability to demonstrate effective pr
oncept and clinical efficacy, and hurdles in regulatory trial design and p
election.
Concepts are being used to treat MR caused by both intrinsic degene
iseases and annular dilatation associated with functional MR (FMR) (Tab
ercutaneous mitral valve approaches can be divided into those that addre
eaflets, which are mainly but not totally being used for intrinsic disease, an
ABLE 1. Percutaneous mitral valve approaches
Leaflet repair
● Evalve Mitraclip (Evalve, Inc, Redwood City, Calif)
● Edwards Mobius Stitch (Edwards Lifesciences, LLC, Irvine, Calif)
Annular remodeling
Coronary sinus annuloplasty
● Cardiac Dimensions Carillon (Cardiac Dimensions, Kirkland, Wash)
● Edwards Monarc (Edwards Lifesciences, LLC)
● St Jude annulus reshaping (St Jude Medical Inc, St Paul, Minn)
● Viacor shape-changing rods (Viacor, Inc, Wilmington, Mass)
Direct annuloplasty
● Guided-delivery anchor cinch plication
● Micardia variable size rings (Micardia, Inc, Irvine, Calif)
● Mitralign suture-based plication (Mitralign, Inc, Salem, NH)
● QuantumCor radiofrequency annulus remodeling (QuantumCor Inc, San Clemente, Calif)
Chamber and annular remodeling
● Ample PS3-left atrium plus annulus (Ample Medical, Foster City, Calif)
● Myocor I Coapsys-left ventricle plus annulus (Myocor, Inc, Maple Grove, Minn)hat use various concepts of annular remodeling in FMR. The Evalve Mitraclip
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LEvalve, Inc, Redwood City, Calif) device and the Edwards
obius Stitch (Edwards Lifesciences, LLC, Irvine, Calif)
evice are based on the concept of the edge-to-edge leaflet
pproximation technique of Alfieri and colleagues.1 Some
48 patients have been enrolled in the various Evalve trials,
ncluding 55 in the EVEREST I registry, 20 in the EVER-
ST II high-risk registry, and the remainder in the EVER-
ST II pivotal trial comparing the Mitraclip in a 2:1 ran-
omization scheme with conventional surgical mitral valve
epair in patients with a lack of A2–P2 coaptation.2 Most of
hese patients have intrinsic degenerative disease of the
eaflets, although 22 patients with FMR have been treated
ith this technique. One must question the inclusion of
atients with FMR in this trial, because the edge-to-edge
echnique used surgically for functional disease has been
hown to be ineffective in the surgical setting.3 Acute pro-
edural success rate leading to less than 2 MR was
chieved in only 61% of the first 104 patients. Seventy-three
ercent of patients remained surgery free at follow-up, and
f those who had undergone surgery, 71% of patients were
epaired and 23% of patients underwent mitral valve re-
lacement. Despite the fact that these results of the percu-
aneous edge-to-edge technique do not meet the expecta-
ions of acceptable surgical results, some degree of
entricular remodeling has been reported to occur with
educed left ventricular systolic and end-diastolic dimen-
ions at 12 months even without complete correction of the
R.2 Enrollment in the pivotal trial is approximately 4
omplete, and additional information to be gained from this
rial includes the results of surgical mitral valve repair.
lthough excellent surgical results from single-center ex-
erience with 92% echocardiographic follow-up and 80%
reedom from greater than 2 MR with isolated posterior
eaflet repair at 12 years have been reported, advocates of
he percutaneous technique have criticized published surgi-
al results as lacking intent-to-treat reporting, echocardio-
raphic follow-up, and core laboratory analysis of results.
his trial will indeed help to establish the true surgical
enchmark. The results of the feasibility trial of the other
evice, the Edwards Mobius stitch, were recently presented
ith 6 of 15 patients improved by at least 1 MR grade at 30
ays. Because of “mixed results, procedural complexity,
nd a perceived limited patient population, the further in-
estigation and device development has been suspended at
resent.”4 Whether this is an indictment of the edge-to-e
oncept or merely an issue with this particular device is not
lear.
FMR is a disease of the left ventricle, not of the mitral
alve per se. MR in dilated cardiomyopathy is caused pri-
arily by apical lateral distraction of the papillary muscles
ethering the leaflets of the valve with secondary annular
ilatation occurring the most in the septal lateral dimension.
urgical correction of FMR is based on overcorrection of S
38 The Journal of Thoracic and Cardiovascular Surgery ● Febrhe annular dilatation to reestablish an adequate surface of
eaflet coaptation by a ring firmly anchored in the fibrous
rigones. Percutaneous approaches for correction of FMR,
ith the exception of the edge-to-edge experience men-
ioned above, all involve some degree of annular remodel-
ng that to varying degrees simulates surgical annuloplasty.
he easy access of the coronary sinus for device delivery
as proved attractive for this approach. Four devices are
elivered through the coronary sinus and primarily remodel
he posterior annulus to cause distraction in the septal di-
ection. However, the article by Lansac and colleagues5 in
his issue points out some of the anatomic issues that may
ffect the ultimate success of mitral annuloplasty performed
hrough the coronary sinus route. Their study on human
adaver hearts found that a coronary sinus annuloplasty at
est achieves a commissure-to-commissure annuloplasty
ather than being anchored in the fibrous trigones, which is
n integral part of the surgical annuloplasty. In addition,
hey found that the coronary sinus was immediately adja-
ent to the left atrial wall and not the posterior mitral
nnulus, with an average distance between the coronary
inus and the annulus of 8 to 14 mm at the coronary sinus
stium, 13 to 20 mm in the middle of the coronary sinus,
nd 7 to 14 mm at the level of the great coronary vein. They
lso found that the circumflex coronary artery was located
etween the coronary sinus and the mitral annulus in 45% of
he cases. On the basis of their anatomic study, Lansac and
olleagues raised appropriate concerns about the ultimate
uccess of coronary sinus-delivered devices. These findings
ere confirmed in other studies by both cadaver dissection
nd 3-dimensional computed tomography reconstruction.6-8
ndeed, these concerns have been realized clinically with the
xperience of 1 device, the CARILLON Mitral Contour
ystem (Cardiac Dimensions, Kirkland, Wash). It was nec-
ssary to remove 2 of 34 implants because of the compro-
ise of the coronary artery circulation resulting in ischemia.
he Monarc (Edwards Lifesciences, LLC, Irvine, Calif) is a
ethering device that actively foreshortens for a 6-week
eriod of time after implantation. Early clinical results with
his device and the CARILLON device are reported to show
ome degree of improvement of MR. Another variable
ompounding the placement of the coronary sinus devices is
he fact that a significant number of candidate patients for
hese devices either have or will have coronary sinus leads
or resynchronization therapy. The impact of additional
ardware in the coronary sinus must be closely examined.
The coronary sinus anatomic issues have been circum-
ented by a number of devices that perform a direct annu-
oplasty. The Mitralign (Mitralign, Inc, Salem, NH) device
erforms a direct suture plication from the ventricular as-
ect while another anchor-and-cinch system also plicates
he posterior annulus. The QuantumCor (QuantumCor Inc,
an Clemente, Calif) device has been demonstrated in the
uary 2008
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Lnimal to remodel the posterior annulus by direct applica-
ion of radiofrequency energy. Two other devices remodel
he mitral annulus by causing a decrease in the septal lateral
imension: the Coapsys device (Myocor, Inc, Maple Grove,
inn) from the ventricular aspect and the Ample P3 septal
hortening system (Ample Medical, Foster City, Calif) via a
ransatrial approach by a bridge-and-tether system anchored
n the coronary sinus and fossa ovalis. Early clinical proof
f concept has been demonstrated with both.
Although preclinical proof of concept and clinical safety
ave been demonstrated with a number of devices, as well
s early clinical efficacy in 2 of the coronary sinus devices,
he lasting clinical benefit is of some concern. As with
urgical mitral annuloplasty, it should be remembered that
MR is a disease primarily of the left ventricle and not of
he mitral valve. Whereas the success of correction of MR
s questionable with optimally placed surgical devices be-
ause of a high recurrence rate and difficulty demonstrating
linical benefit, the challenge to show benefit is even greater
y less correction of the MR with devices delivered through
ither the coronary sinus or other annular remodeling
pproaches.
Two other intriguing options for the correction of MR
orth noting include transcatheter placement of artificial
hords that can be delivered through a transapical approach
nd an early-stage concept of transcatheter mitral valve
eplacement (Endovalve, Endovalve Inc, Princeton, NJ).
Although proof of concept, clinical safety, and some
arly clinical efficacy with percutaneous mitral devices have
een demonstrated, significant challenges remain. Although
he goal of all devices is the correction of MR, trial design
nd clinical end points are totally different for intrinsic
isease and for FMR. Whereas the transcatheter aortic valve
herapies are being introduced in patients with a high sur-
ical risk or no surgical option, the trial of the edge-to-edge
evice is in patients who already have a good clinical
ption. We should keep an open mind toward new thera-
eutic options and await the results of the edge-to-edge
ivotal trial before reaching any firm conclusions. As with
ny less-invasive therapy, however, the question to be an-
wered is how much of a decrement in efficacy is acceptable
or the less invasiveness of the new treatment. Given the
hoice, patients will uniformly choose the least-invasive
ption. With excellent, safe, and minimally invasive surgi-
al approaches with proven longevity already available to
reat degenerative disease of the mitral valve, the bar for
The Journal of Thoraciclinical acceptance of catheter-based approaches should be
high one.
On the other hand, for the therapies to treat FMR where
here is a huge clinical unmet need, the challenge is differ-
nt. The demonstration of clinical therapeutic benefit has
een difficult in optimally performed surgical annuloplasty
rocedures. It will be even more difficult to show therapeu-
ic benefit by devices that of necessity do less than surgical
nnuloplasty. The key will be in the design of clinical trials
o demonstrate efficacy where end points are likely to be
unctional improvement and quality of life rather than mor-
ality. Therefore, sham or blinded trials similar to MADIT II
ay be necessary. There are always major hurdles to sur-
ount in the introduction of any new therapy into clinical
edicine revolving around both safety and the ability to
emonstrate clinical benefit. Although we must not stifle or
bstruct innovation, we also should not let unbridled enthu-
iasm blind ourselves to reality. The challenges of percuta-
eous mitral valve therapy remain formidable and clinical
uccess is by no means assured. A balance should be struck
etween an open mind to new therapy and a critical eye to
he early results.
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